AONN+ Conference Abstracts
November 2019 Vol 10, No 11 | October 25, 2019
Studies demonstrate that many gynecological (Gyn) cancer patients are reluctant to exercise during and after treatment due to fatigue and general weakness. This is the most distressing symptom affecting their quality of life.
November 2019 Vol 10, No 11 | October 25, 2019
Our team implemented a survivorship needs assessment in the Dallas-Fort Worth area to determine the specific needs of the cancer survivors in a specified geographic area.
November 2019 Vol 10, No 11 | October 25, 2019
The Academy of Oncology Nurse & Patient Navigators (AONN+) promotes the goal to share best practices for survivorship and to address the question “Does the Survivorship Care Plan (SCP) Meet Patient Goals?” (Staci Oertle, RN, MSN, APN, AOCNP, AONN+ Survivorship Committee).
Stephanie M. Hoopes, BSN, RN, OCN, ONN-CG, Patricia Leighton, MSN Ed, OCN, ONN-CG, Jo Weathers, RN, BSN, OCN, CBCN, Gina Franco, MSN, ANP-C, LeAnn Perkins, FNP-BC, DipACLM, Pamela Cloys, MSN, ANP-C, Mark A O'Rourke, MD
November 2019 Vol 10, No 11 | October 25, 2019
Per the American Cancer Society, there will be an estimated 20 million cancer survivors by 2026.
November 2019 Vol 10, No 11 | October 25, 2019
Survivorship care plans (SCPs) have played an important role in cancer care for over a decade and are included in the quality metrics or accreditation standards of several institutions, including the American College of Surgeons Commission on Cancer (ACS CoC).
November 2019 Vol 10, No 11 | October 25, 2019
Breast cancer survivors often report depression, anxiety, and stress before and after a breast cancer diagnosis.
Paolo Ghia, MD, Andrzej Pluta, MD, Malgorzata Wach, MD, Daniel Lysak, MD, Tomas Kozak, MD, Martin Simkovic, MD, Polina Kaplan, MD, Iryna Kraychok, MD, Arpad Illes, MD, Javier de la Serna, MD, Sean Dolan, MD, Philip Campbell, MD, Gerardo Musuraca, MD, Abraham Jacob, MD, Eric J. Avery, MD, Jae Hoon Lee, MD, Tianling Chen, MD, Wei Liang, PhD, Priti Patel, MD, Wojciech Jurczak, MD
November 2019 Vol 10, No 11 | October 25, 2019
Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor that has shown clinical benefit in patients with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).
November 2019 Vol 10, No 11 | October 25, 2019
Activating mutations in PIK3CA (the gene encoding the p110α catalytic subunit of class I phosphatidylinositol 3-kinase [PI3K] [PI3Kα]) lead to increased activity of the PI3K pathway and play a role in endocrine treatment resistance in breast cancer.
Dirk Schadendorf, MD, Reinhard Dummer, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Christine-Elke Ortmann, MS, Egbert de Jong, MD, Eduard Gasal, MD, Richard Kefford, MD, PhD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
November 2019 Vol 10, No 11 | October 25, 2019
In the COMBI-AD trial (NCT01682083), 12 months of adjuvant D+T led to significant improvement of RFS versus PBO (hazard ratio [HR], 0.47; P <.001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59% and 54%, respectively.
Sami Diab, MD, Hope S. Rugo, MD, Lida A. Mina, MD, Shannon Puhalla, MD, Reshma Mahtani, DO, N. Lynn Henry, MD, PhD, Neelima Denduluri, MD, Denise Yardley, MD, Yao Wang, MD, Lillian Shahied Arruda, PhD, Iulia C. Tudor, PhD, Eric Gauthier, PharmD, PhD, Akos Czibere, MD, PhD, Jennifer K. Litton, MD, Sara A. Hurvitz, MD
November 2019 Vol 10, No 11 | October 25, 2019
Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2-negative germline BRCA1/2-mutated (gBRCA1/2mut) locally advanced/metastatic breast cancer.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512